Showing results (171-180 of 831) with videos related to

Sort By:
Pageof 84
Future Oncology (London, England)|June 6, 2014
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemiaMichael Hallek, Neil E Kay, Anders Osterborg, et al.
Blood|November 8, 2014
Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemiaJuhi Ojha, Jackline Ayres, Charla Secreto, et al.
American Journal of Epidemiology|September 13, 2002
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective studyJames R Cerhan, Carol A Janney, Celine M Vachon, et al.
British Journal of Haematology|September 28, 2007
Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patientsTait D Shanafelt, Deborah Bowen, Chaya Venkat, et al.
Leukemia|October 7, 2018
Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patientsBryce A Manso, Henan Zhang, Molly G Mikkelson, et al.
Human Molecular Genetics|August 4, 2020
Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk lociHuihuang Yan, Shulan Tian, Geffen Kleinstern, et al.
Cancer|December 6, 2011
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemiaRavin Garg, William Wierda, Alessandra Ferrajoli, et al.
British Journal of Haematology|January 18, 2006
The role of gemtuzumab ozogamicin in acute leukaemia therapyApostolia-Maria Tsimberidou, Francis J Giles, Elihu Estey, et al.
Cancer|March 29, 2002
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemiaJorge Cortes, Deborah Thomas, Adan Rios, et al.
Blood|September 5, 2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upRavin J Garg, Hagop Kantarjian, Susan O'Brien, et al.
Pageof 84